SER-252 completes cohort one, advances to cohort two
SER-252, a novel therapy for advanced Parkinson’s, has completed cohort one in its phase I-B study and advanced to cohort two, with top-line data expected in early 2027.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.